New targeted Crohn’s therapy performs well in phase III trial

HONOLULU – Ustekinumab, a monoclonal antibody targeted against interleukins 12 and 23 (IL-12 and IL-23), met its primary endpoint for control of Crohn’s disease in a multinational phase III trial...